Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.

Mattar A, Logullo AF, Facina G, Nonogaki S, Soares FA, Gebrim LH.

J Cancer Res Clin Oncol. 2011 May;137(5):897-905. doi: 10.1007/s00432-010-0950-4. Epub 2010 Oct 1.

PMID:
20886231
[PubMed - indexed for MEDLINE]
2.

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.

Kurosumi M, Takatsuka Y, Watanabe T, Imoto S, Inaji H, Tsuda H, Akiyama F, Sakamoto G, Ikeda T, Noguchi S.

J Cancer Res Clin Oncol. 2008 Jun;134(6):715-22. Epub 2007 Dec 13.

PMID:
18075758
[PubMed - indexed for MEDLINE]
3.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
[PubMed - indexed for MEDLINE]
Free Article
4.

Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.

Goss PE.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12.

PMID:
16730271
[PubMed - indexed for MEDLINE]
5.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE.

J Clin Oncol. 2005 Apr 10;23(11):2477-92. Epub 2005 Mar 14.

PMID:
15767642
[PubMed - indexed for MEDLINE]
Free Article
6.

Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.

Iwata H, Masuda N, Sagara Y, Kinoshita T, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Tsuda H, Hayashi N, Noguchi S.

Cancer. 2013 Feb 15;119(4):704-13. doi: 10.1002/cncr.27818. Epub 2012 Sep 12.

PMID:
22972694
[PubMed - indexed for MEDLINE]
Free Article
7.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.

PMID:
17200148
[PubMed - indexed for MEDLINE]
Free Article
8.

Focus on anastrozole and breast cancer.

Mokbel K.

Curr Med Res Opin. 2003;19(8):683-8. Review.

PMID:
14687437
[PubMed - indexed for MEDLINE]
9.

A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.

Murray J, Young OE, Renshaw L, White S, Williams L, Evans DB, Thomas JS, Dowsett M, Dixon JM.

Breast Cancer Res Treat. 2009 Apr;114(3):495-501. doi: 10.1007/s10549-008-0027-0. Epub 2008 Apr 26.

PMID:
18438705
[PubMed - indexed for MEDLINE]
10.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group.

J Clin Oncol. 2005 Aug 1;23(22):5108-16. Epub 2005 Jul 5.

PMID:
15998903
[PubMed - indexed for MEDLINE]
Free Article
11.

The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.

Forbes JF.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S2-7.

PMID:
16730270
[PubMed - indexed for MEDLINE]
12.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

PMID:
16382061
[PubMed - indexed for MEDLINE]
Free Article
13.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

PMID:
18812550
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG.

Lancet. 2005 Aug 6-12;366(9484):455-62.

PMID:
16084253
[PubMed - indexed for MEDLINE]
Free Article
15.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
[PubMed - indexed for MEDLINE]
16.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

PMID:
18705406
[PubMed - indexed for MEDLINE]
17.

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.

Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.

Cancer. 2004 Oct 1;101(7):1482-9. Review.

PMID:
15378476
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.

Van Calster B, Van Ginderachter J, Vlasselaer J, Van de Putte G, Berteloot P, Timmerman D, Depypere H, Blomme C, Vlaemynck G, De Jonge E, Van den Broecke R, Vergote I, Amant F, Van Huffel S, Neven P.

Menopause. 2011 Feb;18(2):224-9. doi: 10.1097/gme.0b013e3181eb9f14.

PMID:
20881891
[PubMed - indexed for MEDLINE]
20.

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.

Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J.

J Clin Oncol. 2010 Jul 20;28(21):3411-5. doi: 10.1200/JCO.2009.27.2021. Epub 2010 Jun 14.

PMID:
20547990
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk